Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Excellent news this morning from Destiny Pharma: 99.5% efficacy reported from XF-73 Phase 2b clinical trial. Investor's call available from company website at 11am (in 10 mins), here's the link:
https://www.destinypharma.com/2021/03/29/29-mar-2021-destiny-pharma-phase-2b-results-analyst-and-investor-webcast-and-conference-call-details-monday-29th-march-at-1100-bst/
The contents of this thread will be useful for any new investors (and even existing investors).
Well done all holders !
New article on LTG's recent trading update. Covers new acquisitions, Royal Navy contract and expansion into Moodle territory. Good read for LTG shareholders
https://www.simpvestor.com/plcs-news/2021/1/27/ltg-plc-digital-learning-in-the-pandemic-era
djkbrown, I expect you are pleased with your holding? I estimate you'll have seen a 150%+ return so far?
I've been in since the mid-40s, have taken some profit at points so now LTG is a free ride and then some for me. Still holding more than two-thirds of my original stake. £10 a share would be a dream, though that would value the company at £7 billion, so it would take quite some doing to achieve. My feeling is if LTG keep going the way they have done over the last 4 years with acquisitions and EBITDA, then next couple years could see company get close to £2 billion valuation, so about £2.80 per share. Time will tell.
I recall there being some excitement a while back when LTG engaged Goldman - there was some speculation then for the company to take a step into FTSE. Nasdaq might be interesting, but I think there's enough interest in Blighty for the Board not to need a US listing.
Destiny Pharma's been getting quite a lot of coverage recently which is great news for investors who want to stay informed about the company.
Here's an excellent article on what to look out for in Destiny's near future. Published today from Simpvestor.com:
https://www.simpvestor.com/plcs-news/2021/1/22/destiny-pharmaceuticals-a-defining-moment
I agree. This is a fantastic business which is why I have been a holder for a few years now - suffice it to say I am very happy with how my investment has performed over that time. The company has consistently delivered on targets and now its shown itself to be pandemic proof. The future of learning will be increasingly reliant on software and online assets. LTG has been in that industry since before the pandemic which should put it in a good position to gain more business in the future. Definitely more to come from LTG.
Good discussion on Destiny Pharma on UK Investor Magazine podcast yesterday.
Here is the web link for the podcast, Destiny is discussed from 25 minutes in:
https://ukinvestormagazine.co.uk/biden-and-the-next-chapter-for-global-stock-markets/
Contributors on this board have already discussed the Ineos Oxford Institute for AMR Research (IOI). I wholeheartedly agree with them, this new Institute is great for Destiny Pharma. Below is a link to an Oxford University article relating to the project. The article also contains a 3 minute video which investors will find helpful in understanding the very real threat AMR poses to modern medicine. Shows the importance of drugs like XF-73 and certainly justifies Destiny Board's business model.
https://www.ox.ac.uk/news/2021-01-19-100-million-donation-ineos-create-new-institute-fight-antimicrobial-resistance
Neil Clarke (CEO) is really hot on the promotion front right now. He will also be presenting at the Shares Magazine Investor Forum on 3rd February. Here is the link for those interested in the virtual event:
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-030221
Nice to see some well informed analyses and opinions on this board, its helpful to all investors - holders or prospective. XF-73 looks to be a fantastic proposition, of course we are waiting (and hoping) for success in the clinical trials.
Looks like the Board are mounting a sustained PR campaign to raise the company's profile. Neil Clarke has done a few more interviews and there has been more press coverage recently as well which has helped the share price. The rise from low 30s into 130s within 4 months has inevitably also attracted attention of day traders and momentum players, that is par for the course at this stage of Destiny's development - Gambit gave an analogy using foxes and squirrels which is apt.
Anyhow ... in keeping with this thread's theme on recent information just thought I'd mention that Destiny Pharma will be presenting at the Proactive One2One Investor forum this Thursday 21st Jan. It is a virtual event and for any interested in the event, here is the link:
https://www.proactiveinvestors.co.uk/register/event_details/313#
I’m glad to hear this has been of use Liam. Will add more posts of information as and when I find more
:-)
I agree Neo, given track record/experience of BOD and how far along they are on clinical trials DEST looks fairly undervalued. With NTCD-M3 now I feel it should be valued at £150m M/Cap.
Simpvestor has produced a pretty useful report if you're new to or need a refresher on Destiny Pharma. Here's the link:
https://www.simpvestor.com/plcprofiles/destiny-pharmaceuticals-plc
For in deep dive and "fair valuation" assessments, Equity Development have produced several notes over the past couple years. They can be found here:
https://www.equitydevelopment.co.uk/research/tag/destiny-pharma
Hope this is useful.
GLA
There's been a fair few recent developments with Destiny Pharma. Thought it might be helpful to start a thread which collates some of the information and publications together.
There's a recent interview with the CEO, a couple of Investment Notes from researchers at "Equity Development" and a company report from "simpvestor.com". Will post links below
Starting with a Proactive investors interview with CEO Neil Clarke from 30 Nov '20:
https://www.proactiveinvestors.co.uk/companies/news/935229/destiny-pharma--opportunities-for-quality-assets-that-deliver-solutions-for-infection-prevention--935229.html
This placing is mainly for the acquisition of NTCD-M3 drug and some operations costs.
If XF-73 Phase 2 is successful (from what I am reading we should know about this within a couple months) then I think there will be additional placing for Phase 3 costs at a future date.
After a lot of silence there now seems to be a fair bit of media attention and investor promotion going on. This should be one to watch in the coming weeks.
The Induction Switch App has some solid user reviews. INHC is not just about his app though, it seems like Board are building up a portfolio of channels and apps.
I agree with Khun that this is under the radar, possibly at the behest of the Board as it seems they want to be going about their business without much attention right now.
I think MicroGuide is the only revenue generating product at the moment. Induction Switch was added to NHSX recently so it may start to generate some revenue but would not imagine it to be too much right now.
If Board is to be believed, Switch App has proliferated through NHS staff. However these users are not paying for use. Question for INHC is how can this App (and others) be monetised? Will it be user subscription? Will it be institutional procurement? Perhaps an advertising model (unlikely in my opinion)? Or a combination of these ideas and/or others.
For those who want to get into INHC, my feeling is this will be a long term hold. Find an agreeable price to buy in (currently INHC trading at roughly 30% discount to its IPO price 18 months ago) and then forget about it for a couple years while platforms are developed and new channels are acquired.
Fundamentals and forecasts have not changed at LTG. Therefore it can be reasonably deduced that recent drop in share price is related to do wider global economic issues and other macro-concerns including (but not limited to) US-China trade war, Brexit and Italy budget. While impact of these concerns and uncertainty can be seen by those of us following LTG, it is in fact impacting the equities market as a whole.
LTG continues to acquire and integrate smartly, operates globally, generates more and more revenue in US$ and most of the revenue is recurring through subscription or service models.
Still fully expecting full year results in March 2019 to be in line with the Board's expectation. In fact would not be surprised if results beat forecasts as they have done for the last 4 reporting periods.
AIMHO
Interim Results due on Tuesday 25th September. After a strong week last week, looks likely SP will today close at all time high as anticipation and momentum builds. July Trading Update suggests a 27% increase in revenue relative to the same period last financial year. Operating margins are "robust" which I read as potential for improved profitability. Also looking forward to hearing how purchase of PeopleFluent has integrated into the group as an indicator to the level of impact it will have on revenues for Annual Report in March 2019. There is a broker forecast of 140 but LTG has a history of beating forecasts. Also worth noting that Goldman Sachs came on board in April 2018. Expect this to perform well after Interim results and even better leading up to full results 6 months later.
Shakeypremis you're right to point out that fully absorbed cost of production is higher than the cash cost. The point I was trying to articulate (poorly) is CAML is a low-cost producer that should see benefit to the bottom line from the copper price rally. Thank you for your informed response. With reference to today's price drop, I feel investors would be wise to add this stock despite today's 'blip'. The market will not be informed of the financial upside to CAML until it issues financial reports. I believe there is an interim due in September which should be promising, but I expect the recent price surge will not manifest in fundamentals until full year report in March 2018. For those looking for SP growth, I expect that March be a key date. However, I personally prefer CAML as an earner. Buying now at 215p would return approx 8% in dividends, quite possibly more than that if profits are strong and SP moves in the right direction.
Copper trading above $2.70 per lb ($6300/tonne) is great news for CAML which produces at a cash cost of less than 50 cents per lb from Kounrad mine. If you're not already up to speed about all things CAML, this is a good report to read from simpvestor: hTTps://www.simpvestor.com/plcprofiles/2017/4/2/central-asian-metals-plc
agreed, chairman's statement is promising, as is the growth of sales in the US. NETD acquisition should grow global market with the growth likely coming from its US operations once it is fully integrated into LTG structure. Long term benefit here I think. Found this article on LTG of interest: hTTps://www.simpvestor.com/plcprofiles/2017/3/15/learning-technologies-group-specialist-tech-plc-and-growth-by-acquisition